# US 2008/0306285 A1 · Heat-Labile Prodrugs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306285 A1
- Document ID: US20080306285A1
- Status: Published application
- Kind: A1
- Application number: 12/111,188
- Filed: 2008-04-28
- Published: 2008-12-11
- Earliest claimed: 2007-04-27
- Assignees: Alexza Pharmaceuticals, Inc.
- Inventors: Ron L. Hale; Dennis W. Solas; Kathleen Simis; Amy T. Lu; Peter M. Lloyd
- Web page: https://patentgrep.com/patent/US20080306285A1

## CPC

- C07C 69/96: Esters of carbonic or haloformic acids
- C07C 59/68: the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
- C07D 311/80: Dibenzopyrans; Hydrogenated dibenzopyrans
- C07J 1/0051: {Estrane derivatives}
- C07J 41/0072: {the A ring of the steroid being aromatic}
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07J: STEROIDS (seco-steroids C07C)

## Abstract

Disclosed herein are heat-labile prodrugs, their preparation and uses.

## Claims

### Claim 1

A prodrug of a phenolic drug compound, the prodrug having the general structural formula:
DRUG-O—(CR1R2)nCOOR3
wherein
DRUG-O— is a hydroxyl functional group attached to a carbon atom of an aromatic ring of the phenolic drug compound;
R1, R2 and R3 are independently selected from the group consisting of H, cycloalkyl groups having up to 10 carbon atoms, straight or branched chain alkyl, alkenyl or alkynyl groups of 1 to 10 carbon atoms, wherein the chains thereof (i) may be interrupted by at least one N, S, or O atom, or (ii) may be substituted by at least one group selected from the group consisting of COR4, COOR4 and CON(R4)2, hydrocarbyl aryl groups, aryl groups substituted by at least one group selected from the group consisting of COR4, COOR4, CON(R4)2, N(R4)2, OR4, halogen, SR4, NO2, and R4, mono- bi-cyclic saturated or unsaturated heterocyclic rings, each ring consisting of 3 to 7 members selected from the group consisting of carbon, nitrogen, oxygen and sulfur, CN, COR4, COOR4, CON(R4)2, and C(halogens)3;
R4 is selected from the group consisting of cycloalkyl groups having up to 10 carbon atoms, straight or branched chain alkyl, alkenyl and alkynyl groups having 1 to 10 carbon atoms, straight or branched chain alkyl, alkenyl and alkynyl groups of 1 to 10 carbon atoms wherein the chains thereof may be interrupted by at least on N, S or O atom, hydrocarbyl arl groups, and in the case of —N(R4)2 taken with the other R4 group and N is mono- or bi-cyclic saturated or unsaturated heterocyclic ring, wherein each ring consists of 3 to 7 members selected from the group consisting of carbon, nitrogen, oxygen and sulfur;
n is 1 to 3; and
(B) salts thereof.

### Claim 2 (depends on 1)

The prodrug of claim 1, wherein the phenolic drug compound is selected from the group consisting of Δ9-tetrahydrocannabinol, propofol, and estradiol.

### Claim 3 (depends on 2)

The prodrug of claim 2, wherein R1, R2 and R3 are H, and n is 2.

### Claim 4

A prodrug of a phenolic drug compound, the prodrug having the general structural formula:
wherein
DRUG-O— is a hydroxyl functional group attached to a carbon atom of an aromatic ring of the phenolic drug compound;
R1 is selected from the group consisting of H, cycloalkyl groups having up to 10 carbon atoms, straight or branched chain alkyl, alkenyl or alkynyl groups of 1 to 10 carbon atoms, wherein the chains thereof (i) may be interrupted by at least one N, S, or O atom, or (ii) may be substituted by at least one group selected from the group consisting of COR2, COOR2 and CON(R2)2, hydrocarbyl aryl groups, aryl groups substituted by at least one group selected from the group consisting of COR2, COOR2, CON(R2)2, N(R2)2, OR2, halogen, SR2, NO2, and R2, mono- bi-cyclic saturated or unsaturated heterocyclic rings, each ring consisting of 3 to 7 members selected from the group consisting of carbon, nitrogen, oxygen and sulfur, CN, COR2, COOR2, CON(R2)2, and C(halogens)3;
R2 is selected from the group consisting of cycloalkyl groups having up to 10 carbon atoms, straight or branched chain alkyl, alkenyl and alkynyl groups having 1 to 10 carbon atoms, straight or branched chain alkyl, alkenyl and alkynyl groups of 1 to 10 carbon atoms wherein the chains thereof may be interrupted by at least on N, S or O atom, hydrocarbyl arl groups, and in the case of —N(R2)2 taken with the other R2 group and N is mono- or bi-cyclic saturated or unsaturated heterocyclic ring, wherein each ring consists of 3 to 7 members selected from the group consisting of carbon, nitrogen, oxygen and sulfur; and
(B) salts thereof.

### Claim 5 (depends on 4)

The prodrug of claim 4, wherein the phenolic drug compound is selected from the group consisting of Δ9-tetrahydrocannabinol, propofol, and estradiol.

### Claim 6 (depends on 5)

The prodrug of claim 5, wherein R1 is H.

### Claim 7 (depends on 4)

A method of making a phenolic drug compound comprising heating a composition comprising a prodrug of the phenolic drug compound to a temperature greater than 100°, wherein the prodrug is a prodrug of claim 4.

### Claim 8

A method of making a vapor comprising a phenolic drug compound comprising heating a composition comprising a prodrug of the phenolic drug composition to a temperature sufficient to vaporize at least a portion of the composition to generate a vapor comprising the phenolic drug compound.

### Claim 9 (depends on 8)

The method of claim 8 further comprising condensing the vapor to form an aerosol.

### Claim 10

A prodrug of a phenolic drug compound, the prodrug having the general structural formula:
wherein
DRUG-O— is a hydroxyl functional group attached to a carbon atom of an aromatic ring of the phenolic drug compound;
R1, R2, R3, R4, R5, R6 and R7 are independently selected from the group consisting of H, cycloalkyl groups having up to 10 carbon atoms, straight or branched chain alkyl, alkenyl or alkynyl groups of 1 to 10 carbon atoms, wherein the chains thereof (i) may be interrupted by at least one N, S, or O atom, or (ii) may be substituted by at least one group selected from the group consisting of COR8, COOR8 and CON(R8)2, hydrocarbyl aryl groups, aryl groups substituted by at least one group selected from the group consisting of COR8, COOR8, CON(R8)2, N(R8)2, OR8, halogen, SR8, NO2, and R8, mono-bi-cyclic saturated or unsaturated heterocyclic rings, each ring consisting of 3 to 7 members selected from the group consisting of carbon, nitrogen, oxygen and sulfur, CN, COR8, COOR8, CON(R8)2, and C(halogens)3;
R8 is selected from the group consisting of cycloalkyl groups having up to 10 carbon atoms, straight or branched chain alkyl, alkenyl and alkynyl groups having 1 to 10 carbon atoms, straight or branched chain alkyl, alkenyl and alkynyl groups of 1 to 10 carbon atoms wherein the chains thereof may be interrupted by at least on N, S or O atom, hydrocarbyl arl groups, and in the case of —N(R8)2 taken with the other R8 group and N is mono- or bi-cyclic saturated or unsaturated heterocyclic ring, wherein each ring consists of 3 to 7 members selected from the group consisting of carbon, nitrogen, oxygen and sulfur; and
(B) salts thereof.

### Claim 11 (depends on 10)

The prodrug of claim 10, wherein the phenolic drug compound is selected from the group consisting of Δ9-tetrahydrocannabinol, propofol, and estradiol.

### Claim 12 (depends on 11)

The prodrug of claim 11, wherein R1, R2, R3, R4, R5, R6 and R7 are H.

### Claim 13 (depends on 10)

A method of making a phenolic drug compound comprising heating a composition comprising a prodrug of the phenolic drug compound to a temperature greater than 100°, wherein the prodrug is a prodrug of claim 10.

### Claim 14

A method of making a vapor comprising a phenolic drug compound comprising heating a composition comprising a prodrug of the phenolic drug composition to a temperature sufficient to vaporize at least a portion of the composition to generate a vapor comprising the phenolic drug compound.

### Claim 15 (depends on 14)

The method of claim 14 further comprising condensing the vapor to form an aerosol.

### Claim 16

A prodrug of a phenolic drug compound, the prodrug having the general structural formula:
wherein
DRUG-X— is a carbon atom of an aromatic ring of the phenolic drug compound in the o- or p- position relative to a hydroxyl functional group attached to a different carbon atom of said aromatic ring;
R1 selected from the group consisting of H, cycloalkyl groups having up to 10 carbon atoms, straight or branched chain alkyl groups of 1 to 10 carbon atoms; and
(B) salts thereof.

### Claim 17 (depends on 16)

The prodrug of claim 16, wherein the phenolic drug compound is selected from the group consisting of Δ9-tetrahydrocannabinol, propofol, and estradiol.

### Claim 18 (depends on 17)

The prodrug of claim 17, wherein R1 is H.

### Claim 19 (depends on 16)

A method of making a phenolic drug compound comprising heating a composition comprising a prodrug of the phenolic drug compound to a temperature greater than 100°, wherein the prodrug is a prodrug of claim 16.

### Claim 20

A method of making a vapor comprising a phenolic drug compound comprising heating a composition comprising a prodrug of the phenolic drug composition to a temperature sufficient to vaporize at least a portion of the composition to generate a vapor comprising the phenolic drug compound.

### Claim 21 (depends on 20)

The method of claim 20 further comprising condensing the vapor to form an aerosol.
